

REMARKS

Applicant has represented a complete listing of claims.


The only change made herein relative to the allowed claims is to insert punctuation at line 5 of claim 1 (i.e., a semicolon), and to insert the structures into claims 8 and 12. The content of these claims remains the same. In claims 8 and 12, reference previously was made generally to 26-hydroxyepothilones. For purposes of clarity, applicant wishes for the claims to identify the compounds by structure. Thus, the amendments simply restate the same subject matter of the claims; they do not require any additional searching, and they are patentable for the same reasons previous claims 8 and 12 were found to be patentable.

Summary

The Examiner is invited to contact the undersigned by telephone, at the number listed below, if there are any issues with this amendment, or if it is believed a telephonic communication would facilitate the issuance of the patent.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-6996



Anastasia P. Winslow
Attorney for Applicants
Reg. No. 40,875

Date: March 29, 2007